| Gamifant (emapalumab-lzsg) / SOBI |
NCT05744063: A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients |
|
|
| Active, not recruiting | 4 | 13 | RoW | Emapalumab-Lzsg 5 MG/ML [Gamifant], Gamifant | Swedish Orphan Biovitrum | Primary Hemophagocytic Lymphohistiocytosis | 07/25 | 07/25 | | |
| Completed | 3 | 35 | Europe, Canada, US | Emapalumab | Swedish Orphan Biovitrum | Primary Hemophagocytic Lymphohistiocytosis | 08/21 | 09/22 | | |
| Recruiting | 3 | 41 | Europe, Canada, Japan, US, RoW | Emapalumab, NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO) | Swedish Orphan Biovitrum | Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS | 09/24 | 09/25 | | |
2020-001167-93: A clinical trial investigating efficacy and safety of emapalumab and anakinra in patients with Coronavirus disease (COVID-19) Studio clinico per valutare l'efficacia e la sicurezza di emapalumab e anakinra in pazienti con COVID-19 |
|
|
| Not yet recruiting | 2/3 | 54 | Europe | Kineret, Emapalumab, [Kineret], [Emapalumab], Solution for injection, KINERET - "100 MG/0,67 ML SOLUZIONE INIETTABILE" USO SOTTOCUTANEO SIRINGA PRERIEMPITA 7 SIRINGHE PRERIEMPITE, Gamifant | SWEDISH ORPHAN BIOVITRUM AB (PUBL), Swedish Orphan Biovitrum AB (publ) | SARS-CoV-2 infection Infezione da SARS-CoV-2, Coronavirus disease (COVID-19) Malattia da Coronavirus (COVID-19), Diseases [C] - Virus Diseases [C02] | | | | |
NCT03985423: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH |
|
|
| Terminated | 2/3 | 7 | US | Emapalumab-Lzsg, NI-0501 | Swedish Orphan Biovitrum, Light Chain Bioscience - Novimmune SA | Hemophagocytic Lymphohistiocytoses | 06/21 | 06/21 | | |
NCT06430788: A Study of Emapalumab for Pediatric Aplastic Anemia |
|
|
| Recruiting | 2 | 55 | US | Emapalumab, Gamifant | Memorial Sloan Kettering Cancer Center | Aplastic Anemia, Cytopenia, Hypocellular Marrow | 05/29 | 05/29 | | |
BRIDGE, NCT05787574: A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition |
|
|
| Recruiting | 2 | 39 | US | Emapalumab, Fludarabine and Dexamethasone, Stem Cell Transplant | Memorial Sloan Kettering Cancer Center, Sobi, Inc. | Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System Diseases | 03/27 | 03/27 | | |
NCT05463133: Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists |
|
|
| Recruiting | 1/2 | 50 | US | Sirolimus, Cyclophosphamide, Alemtuzumab, Busulfan, Pheripheral blood stem cells, Emapalumab-Izsg, Tociluzumab, Total Body Irradiation | National Institute of Allergy and Infectious Diseases (NIAID) | Chronic Granulomatous Disease | 12/32 | 12/32 | | |
NCT06439914: First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy |
|
|
| Not yet recruiting | 1 | 6 | US | [89Zr]Zr-DFO-emapalumab, Zirconium Zr 89-DFO-emapalumab | Nerissa T. Viola | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
NCT06285825: A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia |
|
|
| Not yet recruiting | 1 | 32 | US | Emapalumab | M.D. Anderson Cancer Center, Sobi, Inc. | Cytopenia | 08/26 | 08/28 | | |